According to uniQure's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 11.9566. At the end of 2023 the company had a P/S ratio of 20.4.
Year | P/S ratio | Change |
---|---|---|
2023 | 20.4 | 104.99% |
2022 | 9.97 | 444.89% |
2021 | 1.83 | -95.73% |
2020 | 42.9 | -90.04% |
2019 | 430 | 350.97% |
2018 | 95.4 | 107.23% |
2017 | 46.0 | 717.97% |
2016 | 5.63 | -85.66% |
2015 | 39.3 | -13.23% |
2014 | 45.2 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
Amgen AMGN | 5.47 | -54.27% | ๐บ๐ธ USA |
Sanofi SNY | 2.38 | -80.09% | ๐ซ๐ท France |
Sangamo Therapeutics
SGMO | 6.39 | -46.53% | ๐บ๐ธ USA |
bluebird bio
BLUE | 7.97 | -33.34% | ๐บ๐ธ USA |
BioMarin Pharmaceutical BMRN | 5.76 | -51.79% | ๐บ๐ธ USA |
Avidity Biosciences RNA | 238 | 1,891.20% | ๐บ๐ธ USA |